Minor histocompatibility antigen HA-1 peptide–HLA-A*02:01 complex (HA-1/HLA-A*02:01)

The HA-1/HLA-A*02:01 complex is a molecular complex formed when the minor histocompatibility antigen HA-1, a polymorphic human peptide antigen, is presented on the cell surface by the class I major histocompatibility complex (MHC) allele HLA-A*02:01[5]. Recognition of this peptide–MHC complex by CD8+ T cells drives immune responses such as graft-versus-leukemia effects following allogeneic stem cell transplantation. The specificity of HA-1/HLA-A*02:01 makes it an attractive target for immunotherapeutic approaches, including adoptive T cell therapies and peptide vaccines, especially in hematological cancers[5][6]. However, targeting this complex carries risks such as graft-versus-host disease due to its expression on non-malignant hematopoietic cells[5].

Other names

HA-1 antigen–HLA-A*02:01 complexHA-1(H) peptide–HLA-A*02:01HA-1 pMHC (peptide–MHC)minor H antigen–HLA-A2 complexHLA-A*0201-HA-1 complexHA-1H/HLA-A2 complex

Recognition by cytotoxic (CD8+) T cells leading to targeted cell lysis of HA-1+ HLA-A*02:01+ cells. Graft-versus-leukemia or graft-versus-tumor through specific targeting of recipient hematopoietic cells expressing HA-1 peptide presented by HLA-A*02:01